Translation of central nervous system occupancy from animal models: Application of pharmacokinetic/pharmacodynamic modeling

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 1, 2013, Pages 2-6

  Melhem, Murad ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; ROBALZOTAN;

ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; DEPRESSION; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MATHEMATICAL MODEL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SPECIES DIFFERENCE; TRANSLATIONAL RESEARCH;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, NEUROTRANSMITTER;

EID: 84884666404     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199794     Document Type: Article

References (62)

1. Abanades S, van der Aart J, Barletta JA, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, and Zamuner S, et al. (2011) Prediction of repeatdose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 31:944-952.
2. Adolph EF (1949) Quantitative relations in the physiological constitutions of mammals. Science 109:579-585.
3. Alván G, Paintaud G, and Wakelkamp M (1999) The efficiency concept in pharmacodynamics. Clin Pharmacokinet 36:375-389.
4. Andrée B, Hedman A, Thorberg SO, Nilsson D, Halldin C, and Farde L (2003) Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berl) 167:37-45.
5. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99:32-49.
6. A receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316:410-422.
7. A receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy) -3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. J Pharmacol Exp Ther 332:17-25.
8. Baron JC, Comar D, Zarifian E, Crouzel C, Mestelan G, Loo H, and Agid Y (1983) An in vivo study of the dopaminergic receptors in the brain of man using C-ll pimozide and positron emission tomography, in Functional Radionuclide Imaging of the Brain (Magistretti PL ed) pp 337-345, Raven Press, New York.
9. Beal S, Sheiner LB, Boeckmann A, and Bauer RJ, editors (2009) NONMEM User's Guides (1989-2009), ICON Development Solutions, Ellicott City, MD.
10. Bourdet DL, Tsuruda PR, Obedencio GP, and Smith JA (2012) Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. J Pharmacol Exp Ther 341:137-145.
11. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227.
12. Chien JY, Friedrich S, Heathman MA, de Alwis DP, and Sinha V (2005) Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:E544-E559.
13. Cosson VF, Fuseau E, Efthymiopoulos C, and Bye A (1997) Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J Pharmacokinet Biopharm 25:149-167.
14. Cox EH, Langemeijer MW, Gubbens-Stibbe JM, Muir KT, and Danhof M (1999) The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology 90:535-544.
15. Crawley JC, Smith T, Veall N, Zanelli GD, Crow TJ, and Owen F (1983) Dopamine receptors displayed in living human brain with 77Br-p-bromospiperone. Lancet 2: 975.
16. 2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J 13:121-130.
17. de Lange EC (2013) Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn 40:315-326.
18. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
19. Dhillon S (2013) Duloxetine: a review of its use in the management of major depressive disorder in older adults. Drugs Aging 30:59-79.
20. Farde L, Andrée B, Ginovart N, Halldin C, and Thorberg S (2000) PETDetermination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain. Neuropsychopharmacology 22:422-429.
21. Fischman AJ, Alpert NM, and Rubin RH (2002) Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet 41:581-602.
22. Garnett ES, Firnau G, and Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137-138.
23. Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, and Hiemke C, et al. (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988-995.
24. Holford NH and Sheiner LB (1981) Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng 5:273-322.
25. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, and Kapur S (2009) Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 15:2550-2559.
26. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, and Dawson LA (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510:49-57.
27. Ito K, Asakura A, Yamada Y, Nakamura K, Sawada Y, and Iga T (1997) Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Biopharm Drug Dispos 18:293-303.
28. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, and Simmons RM (2004) Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311:576-584.
29. Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60:892-895.
30. (2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520.
31. Kim E, Howes OD, Kim BH, Jeong JM, Lee JS, Jang IJ, Shin SG, Turkheimer FE, Kapur S, and Kwon JS (2012) Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J Cereb Blood Flow Metab 32:759-768.
32. Levy G (1994) Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 56:356-358.
33. 2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther 81:252-258.
34. Liu X, Vilenski O, Kwan J, Apparsundaram S, and Weikert R (2009) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37:1548-1556.
35. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518.
36. Mager DE, Woo S, and Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16-24.
37. 2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818-825.
38. McGuire P, Howes OD, Stone J, and Fusar-Poli P (2008) Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci 29: 91-98.
39. Meibohm B and Derendorf H (1997) Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35:401-413.
40. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, and Houle S (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158: 1843-1849.
41. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, and Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835.
42. Mixcoatl-Zecuatl T and Jolivalt CG (2011) A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. Br J Pharmacol 164: 159-169.
43. Pergolizzi JV, Jr, Raffa RB, Taylor R, Jr, Rodriguez G, Nalamachu S, and Langley P (2013) A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract 13:239-252.
44. Pien HH, Fischman AJ, Thrall JH, and Sorensen AG (2005) Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today 10: 259-266.
45. Pierò A and Locati E (2011) An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with generalized anxiety disorder. Hum Psychopharmacol 26:63-71.
46. Proost JH, Beljaars L, Olinga P, Swart PJ, Kuipers ME, Reker-Smit C, Groothuis GM, and Meijer DK (2006) Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations. Eur J Pharm Sci 27:123-132.
47. Quinn GP, Axelrod J, and Brodie BB (1958) Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline. Biochem Pharmacol 1:152-159.
48. 2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 163:396-401.
49. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, and He H, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci 100:4090-4110.
50. Rowland M, Peck C, and Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73.
51. Seeman P and Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219.
52. Sharma A and Jusko WJ (1996) Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24:611-635.
53. Sheiner LB, Stanski DR, Vozeh S, Miller RD, and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
54. Skljarevski V, Zhang S, Iyengar S, D'Souza D, Alaka K, Chappell A, and Wernicke J (2011) Efficacy of duloxetine in patients with chronic pain conditions. Curr Drug Ther 6:296-303.
55. Smith HS, Smith EJ, and Smith BR (2012) Duloxetine in the management of chronic musculoskeletal pain. Ther Clin Risk Manag 8:267-277.
56. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, and Okubo Y (2003) High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60:386-391.
57. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, Tanada S, and Suhara T (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 185:395-399.
58. 3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 28:608-617.
59. Wagner HN, Jr, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, and Rosenbloom SB, et al. (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264-1266.
60. Ward KW and Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611.
61. West GB, Brown JH, and Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122-126.
62. Willmann JK, van Bruggen N, Dinkelborg LM, and Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591-607.